Abu Dhabi, Hub71-based startup EpiBone, Inc., today announced that the company has successfully closed a convertible note funding round led by Boston-based Kendall Capital Partners, with participation from Lifespan Vision Ventures and EMV Capital plc among others. The financials of the funding round were not disclosed.
EpiBone is a leading regenerative medicine startup at the forefront of skeletal repair treatments. The company sports advanced technology and treatment modalities that leverage autologous and allogeneic stem cells, 3D bioprinting, and bioreactor technology to provide effective bone and osteochondral reconstruction solutions. EpiBone stands on the frontier of regenerative medicine and seeks to disrupt the standard in musculoskeletal treatments.
The company aims to deploy fresh funds to catapult its ongoing pipeline development – paving towards revolutionizing skeletal reconstruction globally.
Speaking of the development, Dr. Nina Tandon CEO and Co-Founder of EpiBone, Inc., in a press statement said,
“We are thrilled to have the continued support of Kendall Capital Partners, along with Lifespan Vision Ventures, EMV Capital plc, and other strategic investors, who share our vision of transforming skeletal repair through groundbreaking science,” she said
“This funding not only affirms the progress we’ve made but also empowers us to bring our innovative regenerative therapies to more patients in need as we explore Thailand and the UAE, both emerging global centers of medical tourism.” she added
Expressing his enthusiasm, David Zhu, Founding Partner of Kendall Capital Partners, added,
“We are proud to lead a syndicate of institutional and strategic investors and family offices in this funding round to support EpiBone’s mission to revolutionize skeletal repair. Thinking globally from the outset is essential for cutting-edge technologies like EpiBone’s, as it accelerates commercialization and amplifies the scale of impact. EpiBone’s innovative approach is poised to transform the landscape of regenerative medicine, and we are thrilled to be part of their journey.”
Dr. Ilian Iliev, CEO of EMV Capital plc, stated,
“Epibone is revolutionizing healthcare with their cutting-edge approach to personalized medicine, offering a solution that not only has the potential to improve patients’ lives but also redefine how we treat complex diseases. They are developing technology that will shape the future of healthcare. We are proud to continue supporting this visionary team as they enter the exciting next chapter of growth and innovation.”
